Protective effect of pioglitazone in rat models of radiation-induced heart injury

doi:10.3969/j.issn.2095-4344.2015.05.004

Abstract

Abstract:

BACKGROUND: There are many positive effects by activation of peroxisome proliferator activated receptor-gamma (PPARγ) signal pathway in cardiovascular system. Angiotensin II is closely related with myocardial fibrosis, however, there are few articles demonstrating that the activation of PPARγ signal pathway can weaken the expression of angiotensin II to improve the radiation-induced heart injury.
OBJECTIVE: To evaluate the effect of angiotensin II type 1 receptor in the rat model of radiation-induced heart injury after PPARγ signal pathway is activated.
METHODS: Sixty rats were randomly and equally divided into five groups: control, pioglitazone, model, radiation + low-dose pioglitazone, radiation + high-dose pioglitazone. In the model, radiation + low-dose pioglitazone, radiation + high-dose pioglitazone groups, rats received 6 MV high energy X-ray irradiation at the range of 1.5 cm × 1.5 cm and the irradiation dose of 300 cGy/min, for 6 hours. Furthermore, rats in the radiation + low-dose pioglitazone and radiation + high-dose pioglitazone groups were given 10 and 20 mg/kg pioglitazone by lavage, for 30 days; rats in the model group were given 2 mL distilled water. In the pioglitazone group, rats were treated with 10 mg/kg pioglitazone by lavage.
RESULTS AND CONCLUSION: After rats were treated with pioglitazone, the heart injury and the heart fibrosis in the irradiated rats were decreased. The expressions of angiotensin II type 1 receptor mRNA and protein in the heart tissue were down-regulated. Experimental findings indicate that, pioglitazone intervention downregulates the expression of angiotensin II type 1 receptor in the rat models of radiation-induced heart injury and activation of PPARγ signal pathway alleviates the radiation-induced heart injury.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: Radiotherapy Injury, Heart Injury, Angiotensin II, Peroxisome Proliferator Activated Receptor

CLC Number:

R318

Song Yang, Wu Rong, Zeng Yue-can, Zhang Zhen-yong, Du Hong-mei. Protective effect of pioglitazone in rat models of radiation-induced heart injury[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(5): 674-680.

Figures/Tables 5

References

[1] Boerma M. Experimental radiation-induced heart disease: past, present, and future. Radiat Res. 2012;178(1):1-6.
[2] Boerma M, Hauer-Jensen M. Potential targets for intervention in radiation-induced heart disease. Curr Drug Targets. 2010; 11(11):1405-1412.
[3] Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev. 2012;20(4):184-188.
[4] Lee PJ, Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev. 2005;13(2):80-86.
[5] Stewart JR, Fajardo LF. Radiation-induced heart disease: an update. Prog Cardiovasc Dis. 1984;27(3):173-194.
[6] Andratschke N, Maurer J, Molls M, et al. Late radiation- heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention. Radiother Oncol. 2011;100(2):160-166.
[7] Finch W, Shamsa K, Lee MS. Cardiovascular complications of radiation exposure. Rev Cardiovasc Med. 2014;15(3): 232-244.
[8] Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. Am J Cardiol. 2013;112(10):1688-1696.
[9] Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys. 2002;29(10):2391-2403.
[10] Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal. 2011; 15(7):1945-1956.
[11] Balonov M. Third annual Warren K. Sinclair keynote address: retrospective analysis of impacts of the Chernobyl accident. Health Phys. 2007;93(5):383-409.
[12] Ermak G, Figge JJ, Kartel NA, et al. Genetic aberrations in Chernobyl-related thyroid cancers: implications for possible future nuclear accidents or nuclear attacks. IUBMB Life. 2003; 55(12):637-641.
[13] Adams MJ, Lipshultz SE, Schwartz C, et al. Radiation- associated cardiovascular disease: manifestations and management. Semin Radiat Oncol. 2003;13(3):346-356.
[14] Liu HR, Tao L, Gao E, et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004; 62(1):135-144.
[15] Hart CM, Roman J, Reddy R, et al. PPARgamma: a novel molecular target in lung disease. J Investig Med. 2008;56(2): 515-517.
[16] Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2006;1(2): 193-209.
[17] Gao D, Ning N, Hao G, et al. Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats. PPAR Res. 2012; 2012:856426.
[18] Ehanire T, Ren L, Bond J, et al. Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. J Mol Med (Berl). 2014. in press.
[19] Chen K, Chen J, Li D, et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension. 2004; 44(5):655-661.
[20] Gao S, Wu R, Zeng Y. Up-regulation of peroxisome proliferator-activated receptor gamma in radiation-induced heart injury in rats. Radiat Environ Biophys. 2012;51(1):53-59.
[21] Wu R, Zeng Y. Does angiotensin II-aldosterone have a role in radiation-induced heart disease? Med Hypotheses. 2009; 72(3):263-266.
[22] 吴荣,马天馨,曾越灿,等.血管紧张素Ⅱ1型受体拮抗剂在大鼠放射性心脏损伤中保护作用的研究[J].中国医科大学学报,2014. in press.
[23] Wang J, MacKenzie JD, Ramachandran R, et al. Identifying neutrophils in H&E staining histology tissue images. Med Image Comput Comput Assist Interv. 2014;17(Pt 1):73-80.
[24] Pei Y, Fan JJ, Zhang XQ, et al. Repairing the osteochondral defect in goat with the tissue-engineered osteochondral graft preconstructed in a double-chamber stirring bioreactor. Biomed Res Int. 2014;2014:219203.
[25] Xia QY, Rao Q, Shen Q, et al. Immunohistochemical study of perivascular epithelioid cell neoplasms. Zhonghua Bing Li Xue Za Zhi. 2013;42(6):381-385.
[26] Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006;58(4):726-741.
[27] Macpherson AM, Archer DF, Leslie S, et al. The effect of etonogestrel on VEGF, oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium. Hum Reprod. 1999;14(12):3080-3087.
[28] Horiuchi M, Iwanami J, Mogi M. Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci (Lond). 2012;123(4):193-203.
[29] Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347(6294):645-650.
[30] Sime PJ. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med. 2008;56(2):534-538.
[31] Genovese T, Cuzzocrea S, Di Paola R, et al. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J. 2005;25(2): 225-234.
[32] Iglarz M, Touyz RM, Viel EC, et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid- dependent hypertension. Hypertension. 2003;42(4):737-743.
[33] Tsukamoto H, She H, Hazra S, et al. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol. 2006;21 Suppl 3:S102-105.
[34] Fliegner D, Westermann D, Riad A, et al. Up-regulation of PPARgamma in myocardial infarction. Eur J Heart Fail. 2008; 10(1):30-38.
[35] Chintalgattu V, Harris GS, Akula SM, et al. PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res. 2007;74(1): 140-150.
[36] Zou Y, Komuro I, Yamazaki T, et al. Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts. Circ Res. 1998;82(3):337-345.
[37] Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol. 1998;30(3): 475-483.
[38] Jawien J, Toton-Zuranska J, Gajda M, et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol. 2012;63(1): 77-85.
[39] Ceravolo GS, Montezano AC, Jordão MT, et al. An Interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: in vivo and in vitro studies. PLoS One. 2014; 9(11): e111117.
[40] Lan TH, Huang XQ, Tan HM. Vascular fibrosis in atherosclerosis. Cardiovasc Pathol. 2013;22(5):401-407.
[41] Zhao SM, Li HW, Guo CY, et al. Cardiac fibrosis in diabetic rats: regulation and mechanism of activation of the PPARgamma signal pathway. Chin J Physiol. 2010;53(4): 262-267.
[42] Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102(15):1834-1839.
[43] Zhuo J, Moeller I, Jenkins T, et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens. 1998;16(12 Pt 2):2027-2037.
[44] Su EJ, Lombardi DM, Siegal J, et al. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension. 1998;31(6):1331-1337.
[45] Laplante MA, Wu R, El Midaoui A, et al. NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. J Hypertens. 2003;21(5):927-936.
[46] Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52(4):639-672.